CelLBxHealth plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANPCF research report →
Price Chart
About the company
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1 system, a medical device engineered to isolate and collect whole circulating tumor cells (CTCs) from the blood of patients with metastatic breast cancer, preparing them for further user-validated analysis. The company also provides the Parsortix PR1 system for general CTC capture and collection from blood samples.
- CEO
- Peter Michael Collins
- IPO
- 2014
- Employees
- 119
- HQ
- Guildford, SU, GB
Get TickerSpark's AI analysis on ANPCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $1.35M-52.8%
- Gross Profit
- $-4,790,223-369.3%
- Op Income
- $-20,201,725
- Net Income
- $-19,505,838-37.1%
- EPS
- $-0.06-14.3%
- OCF Growth
- +32.1%
- FCF Growth
- +32.7%
- 52W High
- $0.02
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 0.41
- RSI (14)
- 0
- Avg Volume
- 156
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ANGLE said commercialization progress was strong, but H1 revenue remained under pressure from difficult market conditions and delayed customer decisions.· September 9, 2025
- 3 pharma projects with Eisai and AstraZeneca were completed, and ANGLE is awaiting discussion of next-stage work.
- A new collaboration with Myriad Genetics could open a larger commercial path for Parsortix through repeat testing, lab deployments, and consumables.
- DNA dual analysis with Illumina was a major technical milestone and is drawing interest from the NHS and molecular partners.
- Published data in Nature Medicine on Parsortix-enabled cluster-buster drug research strengthens the platform’s clinical credibility.
- Cash and R&D tax credits were GBP 6.6 million, with runway said to be unchanged into Q1 2026.
ANGLE did not give revenue or EPS figures on the call, but management said pharma revenue was down year over year, product revenue was flat, operating expenditure was reduced by 12%, and comprehensive loss was reduced by 7%. Cash and R&D tax credits were GBP 6.6 million, and the cash runway was unchanged into Q1 2026. Looking ahead, management said it is targeting completion of clinical lab accreditation by the end of the year, and it reiterated that additional funding will be needed in H2 through one or more sources including commercial milestones, licensing, collaboration income, debt, or equity.
Andrew Newland framed the half as a strong operational period marked by progress on commercialization, but he repeatedly emphasized that market volatility and tariff concerns have slowed deal-making. He highlighted three core growth themes: pharma partnerships, DNA dual analysis, and cluster-cancer research, and he said these areas are building a larger pipeline. His tone was optimistic about strategic momentum, especially around Myriad, the NHS, and future lab accreditation, while still acknowledging revenue disappointment and uncertain timing on conversions.
Ian Griffiths said costs are being managed tightly, with some spend paused or cut back, but he stressed that the business still has a necessary underlying spend because it is regulated and must deliver on milestones. He said the company will need additional funding and that sources could include revenues, commercial milestones, licensing, collaboration income, debt, or equity. He also noted the AIM/biotech fundraising backdrop is challenging, so management is focused on converting progress into signed contracts and measurable milestones.
Analysts pressed management on whether the H2 environment is improving, the potential materiality of NHS studies, and whether publications are helping business development. Newland said Myriad’s decision to collaborate was an encouraging sign, that the NHS opportunity could start with a pilot in its lung-cancer blood test-first program, and that publications are actively used in BD through the company’s medical writing team. On pharma and medtech, management said interest is broad but conversion is taking time, with selling cycles typically around 6 months and often involving pilot work and substantial data sharing.
The bull case is that ANGLE is turning years of platform development into real commercial and clinical interest, with Myriad, multiple pharma players, and the NHS all engaged. Management believes Parsortix is uniquely positioned for repeatable testing, DNA dual analysis, and protein analysis from intact circulating tumor cells, which could support multiple revenue streams.
The main bear case is that revenue is still being hit by delayed decision-making, with pharma revenue down and product revenue flat despite strong operational progress. The company also expects to need additional funding, and management gave no timing visibility on when large pharma or medtech discussions will convert into signed deals.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 43.3%
- Shares Outstanding
- 1.14B
- Float Shares
- 492.31M
Our ANPCF coverage
Recent articles, reports, and earnings notes.
No research on ANPCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANPCF report →CelLBxHealth looking up as it bolsters commercial pipeline
proactiveinvestors.com · Oct 21
CelLBxHealth lands contract with Swiss biotech for clinical study
proactiveinvestors.com · Oct 21
Cellbxhealth signs new statement of work with US pharma company
proactiveinvestors.com · Oct 14
CelLBxHealth's blood test spots hard-to-detect cells from brain tumours
proactiveinvestors.co.uk · Aug 12
CelLBxHealth study detects drug targets on cancer cells rivals would miss
proactiveinvestors.co.uk · Aug 3
CelLBxHealth moves from cutting to converting
proactiveinvestors.co.uk · Jul 15
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
proactiveinvestors.co.uk · Jul 15
CelLBxHealth reaffirms revenue guidance
proactiveinvestors.co.uk · Jul 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.